3rd International Conference on
Obesity and Weight Management
June 04–05, 2026 | Virtual Event
Virtual event
Obesity 2026
Lloyd L Tran
Biomed Industries, Inc, USA
Title : NA-931, a Novel Quadruple IGF-1, GLP-1 and GIP Incretin Receptor Agonist Reduces Body Weight Without Muscle Loss
Abstract:
Updating soon...
Biography:
Lloyd L. Tran is the Chief Executive Officer and of Biomed Industries, Inc. since May 2020. Previously, he served as Chief Scientific Officer at NeuroActiva, Inc, Director of Research & Development at Biomed Pharmaceutical, Inc. Lloyd began his career as a scientist at G.D. Searle, Monsanto (Bayer), and Pfizer. Dr. Tran earned a B.Sc (Honours) in Chemistry from the University of Otago and completed a Ph.D. in Medicinal Chemistry from the University of Wellington, New Zealand.